News
-
Winter spotlight
Wednesday | May 2 2018PHARMACY suppliers wanting to highlight their products for the upcoming cooler season can take advantage of a special Winter Spotlight feature in Pharmacy Daily next week - for details email advertising@pharmacydaily.com.au.
-
Join us at APP2018!
Wednesday | May 2 2018APP delegates can win a Google Home device, which is up for grabs for those who visit Pharmacy Daily in the trade show Pamper Lounge.
-
Eating disorders focus
Wednesday | May 2 2018MINISTER for Mental Health Tanya Davies (pictured) yesterday launched the InsideOut Institute for Eating Disorders and announced it would be home for the first national research hub dedicated to eating disorders.
-
Neuropathic guideline
Wednesday | May 2 2018THE UK National Institute for Health and Care Excellence (NICE) has published new guidelines for the pharmacological management of neuropathic pain in a non-specialist setting.
-
Pharmacotherapy Update #2
Wednesday | May 2 2018PHARMEDUCATION is inviting pharmacists, dentists, nurse practitioners, medical practitioners, nurses and allied health professionals to take part in its second Pharmacotherapy Update, which will take place in Byron Bay, NSW from 28 Oct--03 Nov 2018.
-
Pharmacist sentence
Wednesday | May 2 2018A Newcastle pharmacist has been convicted of supplying a prohibited drug, fined $800 and given an 18-month good behaviour bond, over his involvement in the provision of steroids without prescription.
-
MS under the radar
Wednesday | May 2 2018THE latest MS Report Card published by MS Research Australia reveals multiple sclerosis (MS) is on the rise with new estimations showing 25,600 Australians now live with the condition.
-
Medisca TGA nod
Wednesday | May 2 2018PHARMACEUTICAL compounding company Medisca Australia has been granted an A1 compliant rating of its facility following a successful cGMP inspection by the Therapeutic Goods Administration.
-
Opdivo approval
Wednesday | May 2 2018BRISTOL-MYERS Squibb has announced the TGA registration of its Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease - its ninth cancer indication.
-
New AusBiotech ceo
Wednesday | May 2 2018BIOTECHNOLOGY advocacy group AusBiotech has announced the retirement of ceo Glenn Cross, who is stepping down after 13 years with the organisation.
